Christopher Goetz to Double-Blind Method
This is a "connection" page, showing publications Christopher Goetz has written about Double-Blind Method.
Connection Strength
0.971
-
Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord. 2017 09; 32(9):1335-1336.
Score: 0.133
-
Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar; 28(3):341-6.
Score: 0.099
-
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8.
Score: 0.083
-
Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007 Jan 15; 22(2):179-86.
Score: 0.065
-
Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006 May 09; 66(9):1427-9.
Score: 0.062
-
Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
Score: 0.046
-
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939.
Score: 0.045
-
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000 Sep 26; 55(6):789-94.
Score: 0.042
-
Highlights of the North American and European experiences. Neurology. 1998 May; 50(5 Suppl 5):S15-6.
Score: 0.035
-
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 09; 31(9):1373-80.
Score: 0.031
-
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
Score: 0.029
-
Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial. Mov Disord. 1994 May; 9(3):315-7.
Score: 0.027
-
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50.
Score: 0.026
-
Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
Score: 0.019
-
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
Score: 0.019
-
Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology. 1988 Jul; 38(7):1143-6.
Score: 0.018
-
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23.
Score: 0.018
-
Efficacy of cervical cord stimulation in dystonia. Adv Neurol. 1988; 50:645-9.
Score: 0.017
-
A rating scale for Gilles de la Tourette's syndrome: description, reliability, and validity data. Neurology. 1987 Sep; 37(9):1542-4.
Score: 0.017
-
Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods. Ann Neurol. 1987 Mar; 21(3):307-10.
Score: 0.016
-
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci. 2006 Oct 25; 248(1-2):78-83.
Score: 0.016
-
A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb; 63(2):210-6.
Score: 0.015
-
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
Score: 0.013
-
Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003 Jun 10; 60(11):1756-61.
Score: 0.013
-
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol. 2001 Feb; 58(2):249-54.
Score: 0.011
-
Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000 Mar; 39(3):292-9.
Score: 0.010
-
Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology. 2000 Jan 25; 54(2):458-62.
Score: 0.010
-
Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med. 1999 Sep 23; 341(13):988-92.
Score: 0.010
-
Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology. 1996 Dec; 47(6):1493-5.
Score: 0.008
-
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol. 1995 Jun; 52(6):565-70.
Score: 0.007
-
Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology. 1993 Sep; 43(9):1698-703.
Score: 0.006
-
Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study. Clin Neuropharmacol. 1991 Aug; 14(4):322-9.
Score: 0.006